SCHEMBL29709367

SCHEMBL29709367

COc1cc2c(c(OC)c1OC)C(=O)c1c(cc(O)c(C)c1O)C2=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.70
▸ PIM1 P11309 1/20 0.48
▸ ELANE P08246 3/20 0.45
▸ ACLY P53396 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MAPT P10636 3/20 0.43
▸ GLA P06280 2/20 0.43
▸ LCK P06239 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ LIMK1 P53667 1/20 0.43
▸ LIMK2 P53671 1/20 0.43
▸ STS P08842 1/20 0.43
▸ EGFR P00533 2/20 0.42
▸ CDK4 P11802 2/20 0.42
▸ CCND1 P24385 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29709334 0.91 EPHX2 (0.74) EPHX2PIM1ELANEACLYALDH1A1
SCHEMBL16226676 0.84 EPHX2 (0.86) EPHX2PIM1ELANEACLYALDH1A1
SCHEMBL16932396 0.84 EPHX2 (0.81) EPHX2PIM1ELANEACLYALDH1A1
Chrysoobtusin SCHEMBL16226057 0.82 EPHX2 (1.00) EPHX2PIM1ELANEALDH1A1MAPT
SCHEMBL28872286 0.82 EPHX2 (0.60) EPHX2PIM1ELANEACLYALDH1A1
SCHEMBL28872391 0.81 EPHX2 (0.67) EPHX2PIM1ELANEACLYMAPT
SCHEMBL3272698 0.81 EPHX2 (0.68) EPHX2PIM1ELANEACLYALDH1A1
SCHEMBL28872318 0.81 EPHX2 (0.55) EPHX2PIM1ELANEALDH1A1MAPT
SCHEMBL31322006 0.78 EPHX2 (1.00) EPHX2PIM1ELANEACLYALDH1A1
SCHEMBL16226754 0.78 EPHX2 (1.00) EPHX2PIM1ELANEACLYALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11304927-B2 Bioactive extract, fraction of Cassia occidentalis and formulation thereof for bone regeneration COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2022-04-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11304927-B2 Bioactive extract, fraction of Cassia occidentalis and formulation thereof for bone regeneration BMP4, BMP2, BMP1 EPHX2 3231/4885PIM1 2182/4885ELANE 4141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback